Contact this trialFirst, we need to learn more about you.
Enzyme Inhibitor
Ceralasertib + Trastuzumab Deruxtecan for Solid Tumors
Recruiting1 awardPhase 1
Creve Coeur, Missouri
This trial will find the best dose and safety of ceralasertib when given with trastuzumab deruxtecan to treat patients with solid tumors that have a change in the HER2 gene or protein.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service